Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2020 - 12 - 17 tags : Phase 2 save search
CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin
Published: 2020-12-17 (Crawled : 22:00) - biospace.com/
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: 28.72%
H: 6.2%
C: -10.91%
berubicin approval fda trial phase 2 fda ide
Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis
Published: 2020-12-17 (Crawled : 15:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 2.88%
H: 1.6%
C: 0.4%
covid trial phase 2 psoriasis
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in AcneCompany on track to initiate the TRILOGY Phase 3 program in 2021
Published: 2020-12-17 (Crawled : 15:00) - biospace.com/
VYNE | $2.285 -0.65% -0.66% 19K
|
Health Technology
|
| O: 3.79%
H: 0.0%
C: -3.65%
fda acne phase 3 phase 2
Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study
Published: 2020-12-17 (Crawled : 15:00) - biospace.com/
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 1.62%
H: 5.56%
C: 4.15%
results positive phase 2
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Published: 2020-12-17 (Crawled : 14:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -0.26%
H: 26.97%
C: 24.14%
phase 3 phase 1 phase 2 enroll glioblastoma
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
Published: 2020-12-17 (Crawled : 13:01) - globenewswire.com
VYNE | $2.285 -0.65% -0.66% 19K
|
Health Technology
|
| O: 3.79%
H: 0.0%
C: -3.65%
fda acne phase 2
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
Published: 2020-12-17 (Crawled : 13:01) - globenewswire.com
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: 0.88%
H: 3.35%
C: 0.74%
trial phase 3 phase 1 phase 2
Metacrine Reports Positive Results from Phase 1 Trial of MET642
Published: 2020-12-17 (Crawled : 12:01) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 4.18%
H: 2.64%
C: -5.19%
results positive results positive trial phase 3 phase 1 phase 2 met642
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.